RT @synovialjoints: In Phase 2 trial of Tildrakizumab in active PsA efficacy tended to be lower among patients with como
Tweet Content
In Phase 2 trial of Tildrakizumab in active PsA efficacy tended to be lower among patients with comorbid MetS, with improvements from baseline across efficacy measures generally larger in patients without MetS vs those with MetS @RheumNow #ACR21 Abst#1819 https://t.co/ATxaFz9X2O https://t.co/2iJMNmfUzg
Links
Tildrakizumab Efficacy and Safety in Patients with Psoriatic Arthritis by Metab…
https://bit.ly/3odXyan
Show on Archive Page
On
Display in Search Results
On
PDQ
Off